Exosomes obtained from human adipose-derived stem cells alleviate epileptogenesis in the pentylenetetrazol model of epilepsy.

IF 1.6 4区医学 Q4 NEUROSCIENCES

Neuroreport Pub Date : 2025-02-05 Epub Date: 2025-01-29 DOI:10.1097/WNR.0000000000002133

Fateme Derisfard, Zahra Jafarinezhad, Negar Azarpira, Mohammad Reza Namavar, Hadi Aligholi

{"title":"Exosomes obtained from human adipose-derived stem cells alleviate epileptogenesis in the pentylenetetrazol model of epilepsy.","authors":"Fateme Derisfard, Zahra Jafarinezhad, Negar Azarpira, Mohammad Reza Namavar, Hadi Aligholi","doi":"10.1097/WNR.0000000000002133","DOIUrl":null,"url":null,"abstract":"<p><p>As exosome therapy is a promising treatment in neurological disorders including epilepsy, the present study aimed to evaluate the effects of exosomes obtained from human adipose-derived stem cells (ADSCs) on pentylenetetrazol (PTZ) model of epilepsy in mice. Thirty adult mice were divided into PTZ, diazepam + PTZ, and exosome (5, 10, and 15 µg) + PTZ groups. The exosomes were administered intranasally 30 min before PTZ injection. The seizure latency, tonic-clonic onset, seizure duration, and mortality protection rate were monitored. Also, the level of hippocampal malondialdehyde (MDA), the oxidative stress marker, was evaluated. Exosomes in 5 and 15 µg concentration significantly increased seizure latency. Only 15 µg of exosomes induced a considerable delay in tonic-clonic onset. Seizure duration was significantly attenuated in the 5 µg exosome group. In addition, the 5-µg exosome indicated the highest mortality protection rate. Furthermore, the MDA level was significantly reduced in all animals treated by exosomes. Exosomes obtained from human ADSCs could alleviate epileptogenesis induced by PTZ maybe through reducing hippocampal oxidative stress.</p>","PeriodicalId":19213,"journal":{"name":"Neuroreport","volume":"36 3","pages":"161-168"},"PeriodicalIF":1.6000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroreport","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNR.0000000000002133","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

As exosome therapy is a promising treatment in neurological disorders including epilepsy, the present study aimed to evaluate the effects of exosomes obtained from human adipose-derived stem cells (ADSCs) on pentylenetetrazol (PTZ) model of epilepsy in mice. Thirty adult mice were divided into PTZ, diazepam + PTZ, and exosome (5, 10, and 15 µg) + PTZ groups. The exosomes were administered intranasally 30 min before PTZ injection. The seizure latency, tonic-clonic onset, seizure duration, and mortality protection rate were monitored. Also, the level of hippocampal malondialdehyde (MDA), the oxidative stress marker, was evaluated. Exosomes in 5 and 15 µg concentration significantly increased seizure latency. Only 15 µg of exosomes induced a considerable delay in tonic-clonic onset. Seizure duration was significantly attenuated in the 5 µg exosome group. In addition, the 5-µg exosome indicated the highest mortality protection rate. Furthermore, the MDA level was significantly reduced in all animals treated by exosomes. Exosomes obtained from human ADSCs could alleviate epileptogenesis induced by PTZ maybe through reducing hippocampal oxidative stress.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroreport 医学-神经科学

CiteScore

3.20

自引率

0.00%

发文量

150

审稿时长

1 months

期刊介绍： NeuroReport is a channel for rapid communication of new findings in neuroscience. It is a forum for the publication of short but complete reports of important studies that require very fast publication. Papers are accepted on the basis of the novelty of their finding, on their significance for neuroscience and on a clear need for rapid publication. Preliminary communications are not suitable for the Journal. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool. The core interest of the Journal is on studies that cast light on how the brain (and the whole of the nervous system) works. We aim to give authors a decision on their submission within 2-5 weeks, and all accepted articles appear in the next issue to press.